OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer's 33rd Annual Meeting Nov 06, 2018 8:00am EST
OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting Nov 02, 2018 8:00am EDT
OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions Oct 24, 2018 8:00am EDT
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer Oct 15, 2018 7:30am EDT
OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc. Oct 09, 2018 8:00am EDT
OncoSec Chief Scientific Officer to Present at Advances in Immuno-Oncology USA Congress Oct 08, 2018 8:00am EDT
